ICON Public (NASDAQ:ICLR – Get Rating) will post its quarterly earnings results after the market closes on Wednesday, November 2nd. Analysts expect ICON Public to post earnings of $2.76 per share for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
ICON Public (NASDAQ:ICLR – Get Rating) last issued its earnings results on Wednesday, July 27th. The medical research company reported $2.70 earnings per share for the quarter, topping the consensus estimate of $2.52 by $0.18. ICON Public had a net margin of 2.77% and a return on equity of 10.54%. The company had revenue of $1.94 billion during the quarter, compared to the consensus estimate of $1.93 billion. During the same quarter in the prior year, the firm posted $2.12 EPS. ICON Public’s quarterly revenue was up 122.1% compared to the same quarter last year. On average, analysts expect ICON Public to post $11 EPS for the current fiscal year and $13 EPS for the next fiscal year.
ICON Public Price Performance
Shares of ICON Public stock opened at $196.73 on Wednesday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.61. ICON Public has a 52 week low of $171.43 and a 52 week high of $313.00. The stock’s 50-day simple moving average is $202.14 and its 200-day simple moving average is $215.69. The company has a market capitalization of $16.01 billion, a price-to-earnings ratio of 78.11, a PEG ratio of 1.24 and a beta of 1.01.
Analyst Ratings Changes
Several research analysts have weighed in on ICLR shares. StockNews.com upgraded ICON Public from a “sell” rating to a “hold” rating in a research note on Tuesday, October 11th. Citigroup cut their target price on shares of ICON Public from $315.00 to $290.00 and set a “buy” rating for the company in a research note on Friday, July 8th. William Blair reiterated an “outperform” rating on shares of ICON Public in a research note on Thursday, July 28th. UBS Group began coverage on shares of ICON Public in a report on Wednesday, September 7th. They set a “buy” rating and a $270.00 price objective for the company. Finally, Guggenheim reduced their target price on ICON Public from $278.00 to $268.00 and set a “buy” rating on the stock in a report on Monday, October 10th. Four investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $265.56.
Institutional Trading of ICON Public
Several hedge funds and other institutional investors have recently bought and sold shares of ICLR. Captrust Financial Advisors raised its position in ICON Public by 4.8% in the 2nd quarter. Captrust Financial Advisors now owns 28,338 shares of the medical research company’s stock worth $6,141,000 after purchasing an additional 1,296 shares during the period. KB Financial Partners LLC lifted its stake in shares of ICON Public by 23.4% during the 1st quarter. KB Financial Partners LLC now owns 1,742 shares of the medical research company’s stock worth $424,000 after acquiring an additional 330 shares during the last quarter. Finally, Laurel Wealth Advisors Inc. boosted its holdings in ICON Public by 2.0% during the 1st quarter. Laurel Wealth Advisors Inc. now owns 2,708 shares of the medical research company’s stock valued at $658,000 after acquiring an additional 54 shares during the period. Hedge funds and other institutional investors own 91.28% of the company’s stock.
About ICON Public
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ICON Public, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and ICON Public wasn’t on the list.
While ICON Public currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: news.google.com
